Delcath System Gains Significant Exposure Through Presentations at Several Prominent Scientific Meetings

NEW YORK--Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Delcath System, the Company’s percutaneous hepatic perfusion (“PHP”) technology, is being highlighted in oral discussions and a poster presentation at several prominent scientific meetings taking place during the first quarter of 2008, increasing the technology’s exposure within the medical and scientific communities. The meetings include:

• A poster presentation at the 2008 American Society of Clinical Oncology Gastrointestinal Cancers (ASCO) Symposium, January 25 – 27, in Orlando, Florida
• An oral presentation at the 2008 North American Neuroendocrine Tumor Society Symposium, February 8-9, in Southhampton, Bermuda
• An oral presentation at the Third International Symposium on Regional Cancer Therapies, February 16-18, 2008, in Palm Desert, California
• An oral presentation at the Society of Interventional Radiology Annual Scientific Meeting, March 15-20, 2008 in Washington D.C.
• An oral presentation at the American Hepato Pancreato Biliary Association Annual Meeting, March 27-30, 2008, in Ft. Lauderdale, Florida

“The Delcath System is being highlighted at a record number of important scientific meetings this quarter, a fact that speaks to a positive clinical experience with the technology and the momentum behind its continued study,” commented Richard Taney, President and CEO of Delcath Systems. “Presentations at these meetings are a critical component of increasing scientific awareness and clinical use of the Delcath System. We look forward to translating this exposure into added support for ongoing clinical trials, including the NCI-led Phase III study in metastatic melanoma which is currently recruiting additional clinical sites.”

About Delcath Systems, Inc.
Delcath Systems is a developmental stage company testing its percutaneous perfusion technology. The Delcath System is designed to isolate and deliver high doses of anti-cancer agents to specific organs or regions of the body while minimizing the exposure of the drugs to the rest of the body. It is currently being tested in Phase II and III clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver, including melanomas, neuroendocrine tumors and adenocarcinomas. The Company's intellectual property portfolio currently consists of 28 patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.